» Articles » PMID: 16307630

Buprenorphine Retention in Primary Care

Overview
Publisher Springer
Specialty General Medicine
Date 2005 Nov 26
PMID 16307630
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study assesses the rate and predictors of treatment retention for primary care patients with opioid dependence-prescribed buprenorphine, a long-acting partial opioid agonist.

Methods: Observational cohort study of patients prescribed buprenorphine/naloxone and followed for 6 months in the period after the adoption of buprenophine/naloxone by a primary care practice in Rhode Island. Practice policy precluded patient discharges due to continuing drug use.

Results: Patients (n=41) had a mean duration of opioid use of 15.7 years and most had a history of heroin use (63.4%). Thirty-nine percent of patients transferred from methadone maintenance. At 24 weeks, 59% remained in treatment. Nearly half of dropouts occurred in the first 30 days. Participants with opiate-positive toxicologies at week 1 were more likely to drop out of the program (P<.01) and had a significantly shorter retention time (P<.01) on average. Among other drug use and drug treatment variables, employment and addiction counseling during treatment were significantly associated with treatment retention (P=.03).

Conclusion: Retention rates in a real world, primary care-based buprenorphine maintenance practice reflect those reported in clinical trials. Abstinence during the first week of treatment and receipt of counseling were critical to patient retention.

Citing Articles

Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care.

Williams A, Mauro C, Chiodo L, Huber B, Cruz A, Crystal S Drug Alcohol Depend. 2024; 263:112389.

PMID: 39154558 PMC: 11384240. DOI: 10.1016/j.drugalcdep.2024.112389.


Outpatient-Based Opioid Treatment Engagement and Attendance: A Prospective Cohort Study of Homeless-Experienced Adults.

Fine D, Hart K, Critchley N, Chang Y, Regan S, Joyce A J Gen Intern Med. 2024; 39(15):2927-2934.

PMID: 38987479 PMC: 11576663. DOI: 10.1007/s11606-024-08916-2.


Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.

Hawkins E, Malte C, Hagedorn H, Gordon A, Williams E, Trim R J Addict Med. 2024; 18(3):240-247.

PMID: 38329814 PMC: 11150106. DOI: 10.1097/ADM.0000000000001275.


Peer recovery coaching for comprehensive HIV, hepatitis C, and opioid use disorder management: The CHORUS pilot study.

Martin A, Perryman T, Bernstein J, Taylor J, Cruz R, Muroff J Drug Alcohol Depend Rep. 2023; 7:100156.

PMID: 37113387 PMC: 10126838. DOI: 10.1016/j.dadr.2023.100156.


Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.

Ganapathi L, McFall A, Greco K, Srikrishnan A, Kumar M, Mayer K Drug Alcohol Depend. 2023; 246:109839.

PMID: 37031487 PMC: 10416117. DOI: 10.1016/j.drugalcdep.2023.109839.


References
1.
Peachey J, Lei H . Assessment of opioid dependence with naloxone. Br J Addict. 1988; 83(2):193-201. DOI: 10.1111/j.1360-0443.1988.tb03981.x. View

2.
Strain E, Stitzer M, Liebson I, Bigelow G . Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994; 151(7):1025-30. DOI: 10.1176/ajp.151.7.1025. View

3.
Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G . Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 2000; 94(9):1337-47. DOI: 10.1046/j.1360-0443.1999.94913376.x. View

4.
OConnor P, Fiellin D . Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000; 133(1):40-54. DOI: 10.7326/0003-4819-133-1-200007040-00008. View

5.
Johnson R, Chutuape M, Strain E, Walsh S, Stitzer M, Bigelow G . A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343(18):1290-7. DOI: 10.1056/NEJM200011023431802. View